662 results match your criteria Journal of Opioid Management[Journal]


Biopsychosocial determinants of opioid use disorder (OUD) and implications for maternal and child health research: A scoping review.

J Opioid Manag 2019 Jan/Feb;15(1):77-91

Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee.

Background: Opioid use disorder (OUD) is on the rise among women of reproductive age in the United States, contributing to a marked increase in the incidence of adverse consequences on maternal and child health (MCH). There is a dearth of literature on the biopsychosocial determinants of OUD in MCH populations and their role in the current opioid epidemic. The aim of this study is to examine the epidemiology of OUD in the United States and develop a biopsychosocial research model of OUD among women of reproductive age. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2019.0488DOI Listing
March 2019
1 Read

Opioid-induced constipation in chronic pain: Experience with 180 patients.

J Opioid Manag 2019 Jan/Feb;15(1):69-76

Nurse, Pain Unit, Hospital de Alta Resolución de Guadix, Granada, Spain.

Background: Opioid-induced constipation (OIC) is a common adverse effect of opioid analgesic therapy that significantly affects the patient's quality of life and may lead to poor adherence and treatment failure. Tapentadol, oxycodone/naloxone, and some transcutaneous opioids were associated with less frequent OIC than morphine or oxycodone in controlled clinical trials. However, few studies compare these newer opioids with each other in terms of OIC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2019.0487DOI Listing
March 2019
6 Reads

Tapentadol immediate release for moderate to severe acute post-surgery pain.

J Opioid Manag 2019 Jan/Feb;15(1):51-67

Grünenthal Innovation, Innovation Unit Pain, Clinical Science, Grünenthal GmbH, Aachen, Germany.

Objective: To investigate efficacy and tolerability of tapentadol immediate release (IR) in the treatment of moderate to severe acute pain in three surgical pain models.

Design: Three randomized, double-blind, placebo- and active-controlled, multicenter, phase 3 trials were performed in total hip replacement surgery, abdominal hysterectomy, and bunionectomy with trial medications administered every 4-6 hours as needed for up to 72 hours. Tapentadol IR was included in all trials, oxycodone IR in the total hip replacement trial, and morphine IR in the abdominal hysterectomy and bunionectomy trials; active controls ensured assay sensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2019.0486DOI Listing
March 2019
4 Reads

Effect of different doses of remifentanil on stress response during laparoscopic cholecystectomy.

J Opioid Manag 2019 Jan/Feb;15(1):43-49

Department of Anesthesiology and Intensive Care Medicine, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Rome, Italy.

Objectives: An adequate perioperative analgesia reduces neuroendocrine stress response and postoperative complica-tions. Opioids are the most effective parenteral drugs to control pain and stress response.

Design: This is a prospective randomized double-blinded controlled study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2019.0485DOI Listing
March 2019
2 Reads

Implications of use of opioid-containing analgesics for palliation of acute dental pain.

J Opioid Manag 2019 Jan/Feb;15(1):35-41

Professor, Department of Diagnostic Sciences, University of Pittsburgh School of Dental Medicine, Pittsburgh, Pennsylvania.

Background: Initial palliation of acute dental pain with an opioid-containing pain reliever (OPR) is inappropriate but more likely to occur among the under- and uninsured who are unable to access the customary resources for dental care.

Objective: To assess the implications of palliation with an OPR, the authors determined the prevalence of several health attributes and socioeconomic status (SES) of patients taking prescription or over-the-counter (OTC) palliative medications before they presented to an academically affiliated dental clinic for definitive treatment of acute dental pain.

Methods: Prior palliation with any OPR/antibiotic combination was compared with a self-reported mood disorder, use of a psychotherapeutic or street drug, low SES (on Medicaid or self-payer), or high SES (having commercial dental insurance). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2019.0484DOI Listing

Knowledge and implementation of current opioids guideline among healthcare providers in Manitoba.

J Opioid Manag 2019 Jan/Feb;15(1):27-34

Vice-Dean, Office of Continuing Competency and Assessment, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

Objective: To explore self-perceived knowledge and implementation of current opioid guidelines among healthcare providers, and to assess the effect of an opioid-related educational intervention.

Design: Pre-post.

Setting: Academic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2019.0483DOI Listing

Exploratory study examining associations between prescription opioid dose and delay discounting in patients with chronic pain.

J Opioid Manag 2019 Jan/Feb;15(1):19-25

Department of Psychiatry, Oregon Health & Science University, Portland, Oregon; Department of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon; Oregon Institute for Occupational Health Sciences, Portland, Oregon.

Objective: Although some research has identified correlates of high-dose opioid prescriptions, relatively little is known about factors that lead to higher doses. Delay discounting (DD), defined as the subjective value of a reward declining as a function of the delay to that reward, is an objective measure of impulsivity. DD is commonly studied in the context of addictive behaviors, and findings consistently demonstrate greater DD among individuals with opioid use disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2019.0482DOI Listing
March 2019
1 Read

Opioid utilization patterns among patients with cancer and non-cancer pain.

J Opioid Manag 2019 Jan/Feb;15(1):11-18

Professor of Anesthesiology, Pain Research Center, University of Utah School of Medicine, Salt Lake City, Utah.

Objective: Opioid pain medication continues to be an important treatment option for patients with moderate to severe cancer and non-cancer pain; however, limited evidence is available regarding differences in opioid use between these two populations. The objective of this analysis was to compare real-world opioid use patterns over time in these two populations.

Design: Retrospective analysis of administrative claims data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2019.0481DOI Listing

The role of multimodal analgesia in preventing the development of chronic postsurgical pain and reducing postoperative opioid use.

J Opioid Manag 2018 Nov/Dec;14(6):453-461

Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Chronic postsurgical pain (CPSP) is a possible complication of various surgical procedures, which can impair patients' quality of life while also contributing to chronic opioid use. Multiple biopsychosocial factors put patients at risk for CPSP. Multimodal analgesia with the use of various pharmacologic and regional anesthetic techniques can help reduce the incidence and severity of CPSP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0478DOI Listing
January 2019
1 Read

Factors associated with the prevalence of neonatal abstinence syndrome in West Virginia.

J Opioid Manag 2018 Nov/Dec;14(6):445-452

Department of Graduate Health Sciences, West Liberty University, West Liberty, West Virginia; Department of Natural Sciences and Mathematics, West Liberty University, West Liberty, West Virginia.

Neonatal abstinence syndrome (NAS) is a group of problems associated with withdrawal symptoms of a newborn who was exposed to maternal opiate use while in the womb. West Virginia (WV) is of utmost concern as this state exhibits among the highest rates of opioid abuse and consequently, NAS. In this manuscript, we review factors associated with the prevalence of NAS in WV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0477DOI Listing
January 2019
2 Reads

A nasal abuse potential randomized clinical trial of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.

J Opioid Manag 2018 Nov/Dec;14(6):437-443

Scientific Affairs, PRA Health Sciences, Salt Lake City, Utah.

Objective: This study examined the nasal abuse deterrence of REMOXY ER, a novel high-viscosity extended-release oxycodone formulation.

Design: An Institutional Review Board-approved, single-center, randomized, double-blind, placebo, and active-controlled, four-way crossover study of intranasal REMOXY ER gel, manipulated or intact, and ground oxycodone immediate-release (IR). An open label extension examined pharmacokinetics of OxyContin® ER in the first 20 subjects. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0476DOI Listing
January 2019
3 Reads

Abuse-deterrent properties of REMOXY® ER, a high-viscosity extended-release oxycodone formulation.

J Opioid Manag 2018 Nov/Dec;14(6):429-436

President & CEO, Pain Therapeutics, Inc., Austin, Texas.

Objective: These in vitro studies compared abuse-deterrent properties of REMOXY ER (extended-release oxycodone), a novel, high-viscosity gel formulation, versus the two currently marketed ER oxycodone formulations.

Methods: Tampering methods were tailored to each product to maximize oxycodone release with the least complexity, time, and effort, based on the physical/chemical properties of each formulation. Oral abuse was simulated by extracting oxycodone from each manipulated formulation in Common Ingestible Liquids and in Advanced Solvents (not ingestible and requiring additional separation). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0475DOI Listing
January 2019
3 Reads

Driving under the influence of opioids: What prescribers should know.

J Opioid Manag 2018 Nov/Dec;14(6):415-427

Attorney Pharmacist Consultant, Mid Atlantic PharmaTech Consultants, LLC, Ventnor, New Jersey; Attorney Pharmacists Consultant, Opioid Consulting Educational Solutions, LLC, Ventnor, New Jersey.

Opioids affect the central nervous system and are known to produce dizziness, sleepiness, mood changes, and other actions that in some people have a negative impact on psychomotor or mental performance. The negative effects can be exacerbated in persons who are taking other prescription medications or illegal substances. Opioid-abusing drivers clearly represent an unnecessary danger to the public; although the vast majority of patients taking prescription opioids for pain safely drive to work and other activities, a subset may be impaired, but not be aware of or recognize the problem. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0474DOI Listing
January 2019
3 Reads

A claims analysis of the utilization of tramadol for acute pain in patients prescribed buprenorphine/naloxone for opioid use disorder.

J Opioid Manag 2018 Nov/Dec;14(6):407-413

President Trumed Medical Offices, Fall River, Massachusetts; Clinical Professor, Alpert School of Medicine, Brown University, Providence, Rhode Island.

Objective: To determine the prevalence of tramadol prescribing among commercially insured adults receiving medication-assisted therapy (MAT) with buprenorphine/naloxone.

Design: The authors conducted a cross-sectional descriptive study to evaluate the use of tramadol among patients prescribed buprenorphine/suboxone for MAT.

Setting: This study utilized data from 2010 to 2013 Optum® Clinformatics® Data Mart. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0473DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6476537PMC
November 2019
10 Reads

The natural history of prescription opioid abuse: A pilot study exploring change in routes of administration and motivation for changes.

J Opioid Manag 2018 Nov/Dec;14(6):397-405

Inflexxion, Inc., Waltham, Massachusetts.

Objective: The purpose of this retrospective, observational pilot study was to explore change in route of administration (RoA) and motivation for changing RoA during the course of opioid abuse.

Design: This retrospective pilot study involved collecting and analyzing semistructured interview data.

Setting: Interviews were conducted with patients undergoing outpatient substance abuse treatment at a buprenorphine clinic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0472DOI Listing
January 2019
3 Reads

Assessing risk of opioid misuse in the treatment of chronic pain: Building a practical actuarial approach.

J Opioid Manag 2018 Sep/Oct;14(5):381-391

Undergraduate Student, Department of Psychology, Brigham Young University, Provo, Utah.

Objective: Opioid misuse risk assessment has been highlighted as an important part of clinical practice, but there is a paucity of research identifying an effective approach to assessment. Currently, practitioners use patient history, interviews, and formal questionnaires, and these data are weighed clinically to assign risk. The authors propose the use of an actuarial method-the Bayesian nomogram-as a simple, standard, evidence-based approach to opioid misuse risk assessment. Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/2
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0470DOI Listing
March 2019
8 Reads

Pharmacy-related theft of controlled substances: RxPATROL® findings.

J Opioid Manag 2018 Sep/Oct;14(5):373-380

Director, Investigations and RxPATROL Programs, Department of Corporate Security, Purdue Pharma L.P., Stamford, Connecticut.

Objective: To characterize pharmacy-related theft data reported to the Rx Pattern Analysis Tracking Robberies and Other Losses (RxPATROL®) database during the time periods before (2007-2010) and after (2011-2016) the August 2010 switch to reformulated OxyContin® (oxycodone hydrochloride) extended-release tablets (Purdue Pharma L.P.). Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/2
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0469DOI Listing
March 2019
10 Reads

Evaluation of the oral human abuse potential of Oxycodone DETERx® formulation (Xtampza® ER).

J Opioid Manag 2018 Sep/Oct;14(5):359-372

Director, Altreos Research Partners, Inc., Toronto, Ontario, Canada.

Objective: To further characterize the human abuse potential and pharmacokinetics (PK) of Oxycodone DETERx (Xtampza® ER) after intact and chewed oral administration.

Design: Randomized, double-blind, triple-dummy, active- and placebo-controlled, single-dose, six-period, crossover comparison study.

Setting: Clinical research unit. Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/2
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0468DOI Listing
March 2019
19 Reads

Psychosocial interventions for chronic pain and comorbid prescription opioid use disorders: A narrative review of the literature.

J Opioid Manag 2018 Sep/Oct;14(5):345-358

Vice Chair for Pain Medicine, Department of Anesthesiology; Professor, Anesthesiology and Psychiatry, University of Pittsburgh Medical Center, UPMC Pain Medicine, Centre Commons, Pittsburgh, Pennsylvania.

Objective: Opioid misuse in the context of chronic noncancer pain (CNCP) is a multifaceted and complex issue. As opioid misuse and corresponding rates of addiction and overdose deaths exceed epidemic proportions, there is an urgent need for research in this area. The objective of this review is to evaluate the literature addressing psychosocial interventions targeting CNCP and prescription opioid misuse. Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/2
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0467DOI Listing
March 2019
14 Reads

Dextrophropoxyphene effects on QTc-interval prolongation: Frequency and characteristics in relation to plasma levels.

J Opioid Manag 2018 Sep/Oct;14(5):335-344

Universidad de Buenos Aires, Facultad de Medicina, Departamento de Toxicología y Farmacología, Centro de Vigilancia y Seguridad de Medicamentos e Instituto de Investigaciones Cardiológicas "Prof. Dr. Alberto C. Taquini", Buenos Aires, Argentina.

Objective: To evaluate frequency and risk factors for dextropropoxypheneinduced QT-interval prolongation in the clinical setting.

Design: Prospective, noninterventional, observational, longitudinal cohort approach. Electrocardiograms were blindly evaluated by independent professionals. Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/2
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0466DOI Listing
March 2019
2 Reads

Characteristics of prior emergency departments visits associated with subsequent opioid overdose.

J Opioid Manag 2018 Sep/Oct;14(5):327-333

Department of Emergency Medicine, Staten Island University Hospital, Northwell Health, Staten Island, New York.

Objectives: In this study, we aim to identify and discuss the clinical and demographic characteristics of previous emergency department (ED) patient visits, at one of the only two medical centers in Staten Island, the epicenter of the opioid epidemic within Staten Island, who subsequently present to the ED with an opioid overdose.

Design: This was a retrospective, observational study of all patients presenting to the emergency ED between July 1, 2010 and December 31, 2015.

Setting: The study was conducted at Staten Island University Hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0465DOI Listing
March 2019
2 Reads

Prescribers' perceptions on the impact of hydrocodone rescheduling on geriatric pain management: A qualitative study.

J Opioid Manag 2018 Sep/Oct;14(5):317-326

Assistant Professor, Department of Pharmaceutical Health Outcomes and Policy, University of Houston College of Pharmacy, Houston, Texas.

Objective: To qualitatively assess prescribers) perceptions regarding the consequences associated with hydrocodone rescheduling among geriatric patients being discharged from inpatient settings.

Design: This was a cross-sectional study.

Setting: Two focus groups were conducted by a trained facilitator in a metropolitan academic medical center in January 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0464DOI Listing
March 2019
9 Reads

Clinician opioid prescribing practices and patient utilization of prescribed opioids in pediatrics.

J Opioid Manag 2018 Sep/Oct;14(5):309-316

Professor, Department of Pediatrics, University of California San Diego, San Diego, California; Chief Medical Information Officer, Department of Biomedical Informatics, Rady Children)s Hospital, San Diego, California.

Objective: Little is known regarding clinician prescribing of opioid medications and of patient use of prescribed opioid medications in pediatrics. The authors sought to learn more about pediatric clinician opioid prescribing practices and patient utilization and disposal of prescribed opioids.

Design: Cross-sectional, observational study. Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/2
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0463DOI Listing
March 2019
12 Reads

Provider reasons for discontinuing long-term opioid therapy following aberrant urine drug tests differ based on the type of substance identified.

J Opioid Manag 2018 Jul/Aug;14(4):295-303

Core Investigator, Center to Improve Veteran Involvement in Care, VA Portland Health Care System, Portland, Oregon; Assistant Professor, Department of Psychiatry and School of Public Health, Oregon Health & Science University, Portland, Oregon.

Objective: Urine drug testing (UDT) is increasingly performed as a means of identifying aberrant behavior that may be grounds for discontinuation of long-term opioid therapy (LTOT). Little is known, however, about the ways in which positive UDT results may differentially inform decisions to discontinue LTOT based on the type of substance for which the UDT screened positive. The aim of this study was to examine the likelihood of clinician-initiated discontinuation of LTOT attributed to positive UDT results across three discrete categories of substances: (1) cannabis, (2) alcohol or illicit substances (excluding cannabis), and (3) controlled prescription medications that were not prescribed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0461DOI Listing
December 2018
12 Reads

The impact of preinduction fentanyl dosing strategy on postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.

J Opioid Manag 2018 Jul/Aug;14(4):283-293

Biostatistician, Department of Research, Sir Ganga Ram Hospital, New Delhi, India.

Objective: Postoperative nausea and vomiting (PONV) is commonly attributed to opioid analgesics; consequently, perioperative opioid dosage reduction is a common practice. However, inadequate fentanyl analgesia may have adverse implications (sympathetic activation, pain). We conducted this randomized clinical study to analyze whether preinduction fentanyl 3 µg kg administered by different techniques increases incidence of PONV. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0460DOI Listing
December 2018
1 Read

Opioid use: Case-control analyses of worker's compensation data.

J Opioid Manag 2018 Jul/Aug;14(4):273-281

Rocky Mountain Center for Occupational and Environmental Health, Department of Family & Preventive Medicine, University of Utah School of Medicine, Salt Lake City, Utah.

Objectives: Working-age adults are disproportionately impacted by opioid misuse. Factors associated with opioid misuse in people with workers compensation (WC) claims are not well studied. WC in some states is a "captured" market making it a more efficient site for researching the opioids epidemic. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0459DOI Listing
December 2018
22 Reads

Trends in and predictors of hydromorphone administration in US emergency departments (2007-2014).

J Opioid Manag 2018 Jul/Aug;14(4):265-272

Department of Emergency Medicine, The George Washington University School of Medicine and Health Sciences, Washington, DC.

Objective: To examine recent trends in and predictors of hydromorphone administration in US emergency departments (EDs) compared with other opioids.

Design: Retrospective review of data from the National Hospital Ambulatory Medical Care Survey from 2007 to 2014.

Participants: All adult ED visits where an opioid analgesic was administered were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0458DOI Listing
December 2018
2 Reads

Impact of rescheduling hydrocodone-combination products in an urban Texas county healthcare system.

J Opioid Manag 2018 Jul/Aug;14(4):257-264

Assistant Professor, Department of Radiation Oncology, Baylor College of Medicine, Houston, Texas; Adjunct Assistant Professor, Division of Epidemiology, Human Genetics & Environmental Sciences, UT School of Public Health, Dallas, Texas; Smith Clinic, Attwell Radiation Therapy Center, Houston, Texas.

Objective: The objective of this study was to examine the rescheduling of hydrocodone-combination products (HCPs) and associated changes in prescriber patterns in an urban county healthcare system in Texas.

Methods: Pharmacy data were obtained electronically for tramadol, hydrocodone-acetaminophen, and acetaminophen-codeine from 180 days before and after the schedule change on October 6, 2014. and t tests were used to calculate the significance of changes between the medications over the studied time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0457DOI Listing
December 2018
1 Read

Opioid analgesics prescription in people with and without cancer in France.

J Opioid Manag 2018 Jul/Aug;14(4):245-256

Researcher and Sociologist, Aix Marseille Univ, INSERM, IRD, Economics and Social Sciences Applied to Health & Analysis of Medical Information (SESSTIM), Marseille, France; ORS PACA, South-Eastern Health Regional Observatory, Marseille, France.

Introduction And Objectives: According to World Health Organization recommendations, opioids prescription is a key aspect of improvement in cancer pain relief. However, studies on opioids prescription in France are scarce. This study aimed principally to investigate the impact of cancer on opioids prescription and then to identify factors associated with this prescription, focusing on patients& characteristics impact. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0456DOI Listing
December 2018
6 Reads

Association between the North Carolina Medical Board opioid guideline update and opioid prescriptions in Medicare Part D beneficiaries.

J Opioid Manag 2018 Jul/Aug;14(4):239-243

Associate Professor, Wingate University School of Pharmacy, Wingate, North Carolina.

Objective: To examine if North Carolina (NC) opioid prescribing guidelines were associated with changes in opioid prescribing.

Method: Retrospective secondary analysis of the Medicare Provider Utilization and Payment Data: Part D Prescriber datasets from 2013 to 2015.

Participants: Providers who prescribed at least one opioid from 2013 to 2015 and paid by Medicare Part D. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0455DOI Listing
December 2018
23 Reads

Are physicians fully aware of the potential transgenerational and multigenerational effects of a large opioid misuse in the population?

J Opioid Manag 2018 Jul/Aug;14(4):237

Department of Mental Health, ASL CN1 Saluzzo, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0454DOI Listing
December 2018
1 Read

Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.

J Opioid Manag 2018 May/Jun;14(3):211-221

AstraZeneca, Wilmington, Delaware.

Objective: Efficacy and safety of naloxegol, a peripherally acting µ-opioid receptor antagonist that significantly reduces opioid-induced constipation (OIC), were assessed for patient subgroups defined post hoc by baseline maintenance opioid characteristics.

Design: Post hoc, pooled analysis of data from two 12-week, randomized, double-blind, placebo-controlled, phase 3 studies.

Setting: Two hundred fifty-seven outpatient centers in the United States and Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0451DOI Listing
September 2018
7 Reads

Opioid use in the acute setting: A survey of providers at an academic medical center.

J Opioid Manag 2018 May/Jun;14(3):203-210

Division of Trauma, Acute Care Surgery, and Surgical Critical Care, University of Kentucky HealthCare, Lexington, Kentucky.

Objective: To examine attitudes, beliefs, and influencing factors of inpatient healthcare providers regarding prescription of opioid analgesics.

Design: Electronic cross-sectional survey.

Setting: Academic medical center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0450DOI Listing
September 2018
1 Read

Communication between nurse care managers and patients who take opioids for chronic pain: Strategies for exploring aberrant behavior.

J Opioid Manag 2018 May/Jun;14(3):191-202

Associate Professor of Management, Department of Management, Peter T. Paul College of Business and Economics, University of New Hampshire, Durham, New Hampshire.

Objective: One approach to potential misuse of prescription opioids by patients with chronic pain is team-based collaborative primary care, with primary care visits complemented by frequent visits with nurse care managers (NCMs) specializing in addiction care. However, little is known about the communication strategies NCMs employ in these visits. This study aimed to describe strategies NCMs used with patients when discussing aberrancies encountered during opioid monitoring. Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/1
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0449DOI Listing
September 2018
16 Reads

A qualitative study to develop materials educating patients about opioid use before and after total hip or total knee arthroplasty.

J Opioid Manag 2018 May/Jun;14(3):183-190

Kaiser Permanente Center for Health Research, Portland, Oregon.

Objective: The authors undertook a qualitative study with open-ended, structured interviews to understand patient)s educational needs for patients undergoing total hip and total knee arthroplasty (THA/TKA).

Design: Provider interviews explored their approach with THA/TKA patients on: pain management; barriers to opioid tapering; and recommendations/changes on educational materials to support pain management and opioid reduction. Patient interviews explored their experience, understanding, beliefs surrounding opioids, and recommendations on important content. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0448DOI Listing
September 2018
2 Reads

Opioid use disorder and homelessness in the Veterans Health Administration: The challenge of multimorbidity.

J Opioid Manag 2018 May/Jun;14(3):171-182

Professor, Department of Psychiatry, Yale University School of Medicine, VA Connecticut Healthcare System, West Haven, Connecticut.

Objective: The aim of this study is to estimate the prevalence and sociodemographic and clinical correlates of opioid use disorder (OUD), a major cause of morbidity and mortality in the United States, among homeless veterans nationally in the Veterans Health Administration (VHA).

Design: Administrative data on 256,404 veterans who were homeless and/or had OUD in fiscal year 2012 were analyzed to evaluate OUD as a risk factor for homelessness along with associated characteristics, comorbidities, and patterns of service use. Bivariate analyses and logistic regression were used to compare homeless veterans with OUD to veterans with OUD but no homelessness and homeless veterans with no OUD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0447DOI Listing
September 2018
6 Reads

Daily opioid analgesic use reduces blood insulin levels.

J Opioid Manag 2018 May/Jun;14(3):165-170

Associate Professor, Department of Psychology, The University of Alabama at Birmingham, Birmingham, Alabama.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0446DOI Listing
September 2018
7 Reads

Associations between pain coping and opioid use: One-month follow-up results of a prospective study in a cohort of traumatic injury patients.

J Opioid Manag 2018 May/Jun;14(3):159-163

Associate Professor, Department of Family Medicine and Community Health, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.

Objective: To examine associations between Pain Catastrophizing Scale (PCS) scores and daily opioid dosage in traumatic injury patients.

Design: This was a prospective cohort study with patient assessments at baseline and 1-month following discharge.

Setting: Study visits were conducted at a Regional Level I Trauma Center and by phone at follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0445DOI Listing
September 2018
2 Reads

Letter to the Editor: A Case for Opioid Education and Training for Medical Students, Residents, and Allied Health Staff: Response to "Educational Intervention for Physicians to address the risk of Opioid Abuse".

J Opioid Manag 2018 May/Jun;14(3):157

Department of Anesthesiology and Perioperative Medicine Queen's University, Kingston General Hospital Kingston, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0452DOI Listing
September 2018
3 Reads

Does nalbuphine have a niche in managing pain?

J Opioid Manag 2018 Mar/Apr;14(2):143-151

Department of Pharmacy Practice and Science, University of Maryland, Baltimore, Maryland.

Nalbuphine has been commercially available for 40 years for the treatment of acute pain; few studies have centered on management of chronic pain. Nalbuphine unique pharmacology is an advantage in pain management. It is µ antagonist, partial κ agonist for G-proteins and beta-arrestin-2. Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/1
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0441DOI Listing
July 2018
7 Reads

Long-term opioid users with chronic noncancer pain: Assessment of opioid abuse risk and relationship with healthcare resource use.

J Opioid Manag 2018 Mar/Apr;14(2):131-141

Teva Pharmaceuticals, Frazer, Pennsylvania.

Objective: Identify opioid abuse risk factors among chronic noncancer pain (CNCP) patients receiving long-term opioid therapy and assess healthcare resource use (HRU) among patients at elevated abuse risk.

Design: Data were obtained from an integrated administrative claims database. Classification and Regression Tree (CART) analysis identified risk factors potentially predictive of opioid abuse, which were used to classify the overall population into cohorts defined by levels of abuse risk. Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/1
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0440DOI Listing
July 2018
8 Reads

Oxycodone is safe and effective for general anesthesia.

J Opioid Manag 2018 Mar/Apr;14(2):125-130

Clinic for Orthopaedics and Trauma Surgery, Rheinische Friedrich-Wilhelms-Universität, Bonn, Germany.

Purpose: In clinical practice, using different opioid analgesics is common during the induction and maintenance of general anesthesia and for postoperative analgesia. However, if the opioid analgesic could be limited to a single drug, we hypothesized that the risk of adverse drug interactions could be reduced, with fewer adverse effects. We examined the use of oxycodone as a single opioid in a well-defined cohort of orthopedic patients undergoing general anesthesia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.jom.2018.0439DOI Listing
July 2018
8 Reads

The effects on patient retention after opioid weaning in an internal medicine residency clinic.

J Opioid Manag 2018 Mar-Apr;14(2):117-123

Chief Resident, Kettering Medical Center Internal Medicine Residency, Miamisburg, Ohio.

A retrospective, cross-sectional study was completed on 220 patients to determine the effects of implementation of an aggressive policy to curb opioid misuse/abuse in an internal medicine residency clinic. Our findings suggest that the development of a clear and consistent protocol for approaching patients on chronic controlled substances, as well as the initiation of regular didactic sessions addressing chronic pain and pain management, led to a dramatic reduction in the number or opioid prescriptions written by our resident providers without much reduction in patient volume. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0438DOI Listing
July 2018
2 Reads

Does familiarity with CDC guidelines, continuing education, and provider characteristics influence adherence to chronic pain management practices and opioid prescribing?

J Opioid Manag 2018 Mar-Apr;14(2):103-116

Psychology, Stony Brook University, Stony Brook, New York.

Objectives: (1) To assess providers' experience and knowledge of chronic noncancer pain (CNCP) management. (2) To assess providers' utilization of the Centers for Disease Control and Prevention (CDC) 2016 Guideline for Prescribing Opioids for Chronic Pain. (3) To assess the influence of the 2016 CDC guideline on provider confidence in managing CNCP and adherence to the CDC recommendations. Read More

View Article

Download full-text PDF

Source
http://www.wmpllc.org/ojs-2.4.2/index.php/jom/article/view/1
Publisher Site
http://dx.doi.org/10.5055/jom.2018.0437DOI Listing
July 2018
4 Reads

Assessment of outcomes following high-dose opioid tapering in a Veterans Healthcare System.

J Opioid Manag 2018 Mar/Apr;14(2):89-101

Clinical Pharmacy Specialist, Pain Management/Palliative Care, Department of Veterans Affairs Medical Center, North Florida/South Georgia Veterans Health System, Gainesville, Florida.

Objective: To assess the impact of tapering of chronic high dose opioid therapy in veterans prompted by the implementation of the Opioid Safety Initiative in 2013.

Design: IRB and VA Office of Research and Development-approved retrospective, observational chart review.

Setting: North Florida/South Georgia Veterans Health System Patients: Veterans on high dose opioid therapy (≥300 mg of morphine equivalents per day) for chronic non-cancer pain as of 1/1/2012 with an opioid agreement discontinuation note documented in the medical record were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0436DOI Listing
July 2018
4 Reads

Safety profile of intraoperative methadone for analgesia after major spine surgery: An observational study of 1,478 patients.

J Opioid Manag 2018 Mar/Apr;14(2):83-87

Department of Anesthesiology, University of Virginia, Charlottesville, Virginia; Department of Neurosurgery, University of Virginia, Charlottesville, Virginia.

Objective: To investigate the incidence of perioperative adverse events in patients receiving intravenous methadone for major spine surgery.

Design: Retrospective review of perioperative records from March 2011 and February 2016.

Setting: University of Virginia Healthsystem. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0435DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6383150PMC
July 2018
10 Reads

The parenteral opioid shortage: Causes and solutions.

J Opioid Manag 2018 Mar/Apr;14(2):81-82

Professor, Southern Illinois University-Edwardsville School of Pharmacy, Edwardsville, Illinois.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0434DOI Listing
July 2018
1 Read

Sourcing of opioid analgesics for nonmedical use: Are veterinarians the latest frontier?

J Opioid Manag 2018 Mar/Apr;14(2):77-79

Addiction Unit (PROAD), Department of Psychiatry, Universidade Federal de São Paulo (UNIFESP), Sao Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0433DOI Listing
July 2018
3 Reads

Hydromorphone use for acute pain: Misconceptions, controversies, and risks.

J Opioid Manag 2018 Jan/Feb;14(1):61-71

Department of Emergency Medicine, Rutgers New Jersey School of Medicine, Newark New Jersey.

Hydromorphone (HM) is a potent opioid analgesic that is commonly administered in the emergency department (ED) and other acute care settings, such as medical surgical wards. In recent years, there has been a significant increase in the ED administration of HM relative to other opioids. Although HM is an effective analgesic, its use has been commonly implicated in adverse drug events and medication errors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5055/jom.2018.0430DOI Listing
May 2018
7 Reads